Juno's JCAR015 Phase II on clinical hold

Juno Therapeutics Inc. (NASDAQ:JUNO) fell $11.68 (29%) to $29.14 in early after-hours trading Thursday after FDA placed a clinical hold on the Phase II ROCKET trial of JCAR015 to treat relapsed or

Read the full 324 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE